Skip to main content
OpenTrials
Completed

NCT Number: NCT02795403

HCV Virions Bound Proteins

The emergence of hepatocellular carcinoma (HCC) has prompted a search for a thorough understanding of the biology of one of its major causative agents, the hepatitis C virus (HCV). HCV particles acquire via budding and encapsidation cellular proteins. There is mounting evidence on several viral species that virion-bound proteins are prone to be involved either at the replication, budding/egress or entry/release steps of the viral cycle.

Identifying such targets may yield ideal candidates for gaining insight on the dependence of HCV upon a restricted subset of host proteins, therefore providing refined sets of genetically stable targets for therapy. This project's goals are to set up adequate conditions for robust and reproducible purification of HCV virions in clinical samples, followed by the identification of their HCV-bound host proteins and the characterization of their functions. Proteomics profiling of HCV particles purified from clinical samples will be overlaid with proteins identified and characterized in cell culture grown HCV particles during my post-doctoral training, using clinical biomarker discovery grade criteria. Targets identified in both samples sets will be subjected to in vitro investigations using HCV-replicating cells. Conventional biochemical and imaging methods will be used in order to: (i) ascertain their physical association with HCV virions; (ii) define the modalities of their interaction with HCV proteins; (iii) decipher the topology and subcellular localization of their association with HCV proteins and virions; (iv) quantitatively assess their functional involvement in particle budding, egress or secretion and infectivity. A candidate that yielded satisfactory results in these experiments will be disclosed and further investigated at the level of structural biology, in collaborative research programs.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service d'Hépato-Gastroentérologie Lyon Croix-Rousse Hospices Civils de Lyon

Lyon, 69004, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult> 18 and <60 years
  • Infected with HCV genotype 1 HCV antibody positive.
  • positive viremia for more than 6 months
  • Viremia> 106 IU / ml.
  • nonresponders to previous treatment and without antiviral treatment for 2 months.
  • For control samples: Patients responders to previous treatment and without antiviral treatment for 2 months.

Exclusion criteria

  • Patient receiving or having received antiviral treatment within two months.
  • patient with against-indication for a blood sample of 150 ml
  • immunosuppressive therapy patient
  • Patient with liver disease other than hepatitis C.
  • Patients with cirrhosis.
  • patient with hepatocellular carcinoma.
  • Patients with one or more severe co-morbidities defined as:
  • Co-infection with HIV or HBV.
  • hematological malignancies changing or aplasia
  • Insulin-dependent diabetes
  • dialyzed chronic renal failure
  • Heart failure
  • Persons subject to legal protection or the subject of a safeguard measure of justice not affiliated with a social security scheme or not beneficiaries of such a scheme
  • Pregnant women

Treatment and study plan

blood draw of 150ml, twice

Other

Primary outcomes

  1. Qualitative identification (unit used: Protein Prophet score) of a given virion-bound protein in purified virions preparations

    Time frame: One to two years after mass spectrometry identification of the candidate

    Protein prophet scores allow one to estimate the robustness of identification of a given protein in MS approaches.

  2. Quantitative evaluation of its implication in viral morphogenesis (unit used: TCID50).

    Time frame: One to two years after mass spectrometry identification of the candidate

    TCID50 units are infectivity units routinely used in HCV research for viral infectivity quantification.

  3. Quantitative evaluation of viral entry (unit used: HCV RNA /GUS mRNA copy ratios).

    Time frame: One to two years after mass spectrometry identification of the candidate

    HCV RNA /GUS mRNA copy ratios are derived from the 2^delta(delta Ct) method.

Secondary outcomes

  1. Comparison of clinical virions datasets with in vitro grown virions datasets

    Time frame: One to two years after mass spectrometry identification of the candidate

    Proteins identified from viral particles purified from clinical samples will be compared to proteins identified in viral particles from cells of human hepatocarcinoma (Huh7.5) infected with HCV and from which data are published.

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Hepatitis C Virus Particles-bound Human Proteins : Identification in Clinical Samples and Implication in the Viral Life Cycle

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Jun 10, 2016
Registry last updated
Sep 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.